Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Cash flows from operating activities:
Net income	$ 2,017.6	$ 1,745.0
Adjustments to reconcile net income to net cash flows from operating activities:
Depreciation and amortization	325.1	292.5
Share-based compensation	84.1	93.7
Deferred income taxes	(30.2)	(90.6)
Other	19.8	(5.8)
Changes in operating assets and liabilities, net:
Accounts receivable	(65.0)	(38.9)
Inventory	(128.3)	(81.3)
Accrued expenses and other current liabilities	(162.3)	(169.9)
Current taxes payable	(151.7)	102.0
Other changes in operating assets and liabilities, net	50.1	(66.4)
Net cash flows provided by operating activities	1,959.2	1,780.3
Cash flows from investing activities:
Proceeds from sales and maturities of marketable securities	2,823.6	975.5
Purchases of marketable securities	(3,833.3)	(2,045.0)
Acquisitions of business, net of cash acquired	0.0	(198.8)
Purchases of property, plant and equipment	(263.7)	(227.7)
Contingent consideration related to Fumapharm AG acquisition	600.0	250.0
Other	(65.9)	(10.1)
Net cash flows used in investing activities	(1,939.3)	(1,756.1)
Cash flows from financing activities:
Purchase of treasury stock	0.0	(42.2)
Proceeds from issuance of stock for share-based compensation arrangements	(23.9)	(34.7)
Excess tax benefit from share-based awards	9.0	69.7
Other	1.1	15.0
Net cash flows provided by financing activities	34.0	77.2
Net increase in cash and cash equivalents	53.9	101.4
Effect of exchange rate changes on cash and cash equivalents	0.1	(24.2)
Cash and cash equivalents, beginning of the period	1,308.0	1,204.9
Cash and cash equivalents, end of the period	$ 1,362.0	$ 1,282.1